Tecovirimat

Overview

Tecovirimat (ST-246) is an orally bioavailable and selective compound against orthopoxviruses including vaccinia, monkeypox, camelpox, cowpox, ectromelia (mousepox), smallpox and variola viruses. Tecovirimat is evaluated against vaccinia, cowpox virus, ectromelia virus with EC 50 values of 0.01 μM, 0.48 μM and 0.05 μM, respectively. Tecovirimat targets the orthopoxvirus protein VP37 which is necessary for membrane envelopment of intracellular mature virus particles to form enveloped virus. Tecovirimat exerts antiviral activity on the target of the cowpox virus V061 gene , which is homologous to vaccinia virus F13L , encoding a major envelope protein (p37) required for production of extracellular virus.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Viral Infection | Products > Disease Areas > Orthopoxvirus Infection | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Infection | Products > Signaling Pathways > Orthopoxvirus | Products > Signaling Pathways > Arenavirus

Product Information

• Catalog No.: HY-14805
• CAS No.: 869572-92-9
• Molecular Formula: C19H15F3N2O3
• Molecular Weight: 376.33
• Purity: 99.88%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (6.64 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source